Open access
Open access
Powered by Google Translator Translator

Infectious Diseases (all articles)

Bioethics | People who want organ transplants must get the COVID-19 vaccine, a hospital says.

8 Oct, 2021 | 10:21h | UTC

People who want organ transplants must get the COVID-19 vaccine, a hospital say – NPR

 

Opinion | Covid-19 keeps delivering lessons about health care worker burnout. Will we learn them?

8 Oct, 2021 | 10:18h | UTC

Covid-19 keeps delivering lessons about health care worker burnout. Will we learn them? – STAT

 

Commentary on Twitter

 

U.S. Data: Drug-resistant Infections led to $1.9 billion in health care costs, more than 10,000 deaths among older adults in one year.

8 Oct, 2021 | 10:11h | UTC

News release: Drug-resistant Infections Led to $1.9 Billion in Health Care Costs, More Than 10,000 Deaths Among Older Adults in One Year – Infectious Diseases Society of America

Original study: Mortality, Length of Stay, and Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Elderly Hospitalized Patients in the United States – Clinical Infectious Diseases

Commentaries:

Urgent, Comprehensive Federal Action Needed To Stem Mortality and Medicare Costs Associated With Antimicrobial Resistance – Clinical Infectious Diseases

Study highlights impact of antibiotic resistance on older Americans – CIDRAP

 

Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

7 Oct, 2021 | 10:55h | UTC

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar – New England Journal of Medicine

Related: Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

 

Commentary on Twitter

 

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

7 Oct, 2021 | 10:51h | UTC

Myocarditis after Covid-19 Vaccination in a Large Health Care Organization – New England Journal of Medicine

Commentary: Studies Highlight Rarity of Myocarditis With mRNA COVID-19 Vaccines – TCTMD

Related Study: Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel – New England Journal of Medicine

 

Commentaries on Twitter

 

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

7 Oct, 2021 | 10:49h | UTC

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel – New England Journal of Medicine

Commentary: Studies Highlight Rarity of Myocarditis With mRNA COVID-19 Vaccines – TCTMD

Related study: Myocarditis after Covid-19 Vaccination in a Large Health Care Organization – New England Journal of Medicine

 

Commentaries on Twitter

 

Systematic Review: Administration of antimalarial drugs to whole populations for reducing malaria.

7 Oct, 2021 | 10:36h | UTC

Administration of antimalarial drugs to whole populations for reducing malaria – Cochrane Library

Original study: Mass drug administration for malaria – Cochrane Library

 

Commentary on Twitter

https://twitter.com/CochraneUK/status/1444724442094088195

 

Perspective | No one is safe until we are all safe.

7 Oct, 2021 | 10:47h | UTC

No one is safe until we are all safe – Science Translational Medicine

Commentary: Covid ‘still running rampant’ worldwide, warns creator of Oxford vaccine – The Guardian

Related: Opinion: Vaccine Nationalism Harms Everyone and Protects No One

 

Commentary on Twitter

 

WHO approves first ever malaria vaccine for children at risk.

7 Oct, 2021 | 10:40h | UTC

WHO recommends groundbreaking malaria vaccine for children at risk – World Health Organization

Commentaries:

WHO Approves First Ever Malaria Vaccine – Health Policy Watch

A historic day for malaria – reaction to WHO decision on the RTS,S vaccine – London School of Hygiene & Tropical Medicine

In major decision, WHO recommends broad rollout of world’s first malaria vaccine – STAT

Why the WHO approval of the first malaria vaccine is a big deal – Vox

WHO greenlights the world’s first malaria vaccine — but it’s not a perfect shot – NPR

The World Health Organization Just Endorsed The World’s First Malaria Vaccine – TIME

WHO Backs Widespread Use Of First Malaria Vaccine – Forbes

World’s 1st malaria vaccine recommended by WHO – LiveScience

 

Commentaries on Twitter

(thread – click for more)

 

RCT: Immediate drainage did not improve outcomes compared to postponed intervention in patients with infected necrotizing pancreatitis.

7 Oct, 2021 | 10:35h | UTC

Immediate versus Postponed Intervention for Infected Necrotizing Pancreatitis – New England Journal of Medicine

 

Sweden, Denmark pause Moderna COVID-19 vaccine for younger age groups.

7 Oct, 2021 | 10:45h | UTC

Sweden, Denmark pause Moderna COVID-19 vaccine for younger age groups – Reuters

 

Cohort Study: Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumor types in 61 countries.

6 Oct, 2021 | 10:09h | UTC

Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study – The Lancet Oncology

 

Commentary on Twitter (thread – click for more)

 

Opinion | Why Are Americans Still—Still!—Wearing Cloth Masks?

6 Oct, 2021 | 10:04h | UTC

Why Are Americans Still—Still!—Wearing Cloth Masks? – The Atlantic

Related:

Evidence shows that, yes, masks prevent COVID-19 – and surgical masks are the way to go.

Face masks for COVID pass their largest test yet – “A rigorous study finds that surgical masks are highly protective, but cloth masks fall short”.

[Preprint] Largest study of masks yet details their importance in fighting Covid-19.

 

Commentary on Twitter

 

EMA recommendations on extra doses and boosters of BioNTech/Pfizer and Moderna mRNA vaccines.

6 Oct, 2021 | 10:15h | UTC

Comirnaty and Spikevax: EMA recommendations on extra doses and boosters – European Medicines Agency

Related: The difference between COVID-19 ‘third doses’ and ‘boosters’ – Emory News Center

 

Commentary on Twitter

 

What we know — and don’t know — about Merck’s new Covid-19 pill.

6 Oct, 2021 | 10:07h | UTC

What we know — and don’t know — about Merck’s new Covid-19 pill – STAT

Related:

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Systematic review: Pretomanid for tuberculosis.

6 Oct, 2021 | 08:51h | UTC

Pretomanid for tuberculosis: a systematic review – Clinical Microbiology and Infection

Related:

Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.

WHO announces updates on new molecular assays for the diagnosis of tuberculosis (TB) and drug resistance

WHO announces updated definitions of extensively drug-resistant tuberculosis

 

Supplement: Triumphs of Vaccination.

6 Oct, 2021 | 08:55h | UTC

Homepage: Triumphs of Vaccination – The Journal of Infectious Diseases

Triumphs of Immunization

Pertussis (Whooping Cough)

Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease

The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease

Hepatitis B Vaccines

Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe

Rubella Eradication: Not Yet Accomplished, but Entirely Feasible

Human Papillomavirus Vaccines

Smallpox

Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster

Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication

Influenza Vaccines: Successes and Continuing Challenges

Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination

Herpes Zoster Vaccines

Overview of the United States’ Immunization Program

The World of Immunization: Achievements, Challenges, and Strategic Vision for the Next Decade

 

Cohort study: Acute myocarditis following COVID-19 mRNA vaccination in adults aged 18 years or older is rare, and most cases are not severe.

5 Oct, 2021 | 10:07h | UTC

Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older – JAMA Internal Medicine

Editorial: COVID-19 Messenger RNA Vaccination and Myocarditis—A Rare and Mostly Mild Adverse Effect

 

Commentary on Twitter

 

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

5 Oct, 2021 | 10:09h | UTC

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study – The Lancet

Commentary: Expert reaction to study on Pfizer-BioNTech vaccine effectiveness up to 6 months – Science Media Centre

 

Commentary on Twitter

 

RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.

5 Oct, 2021 | 10:06h | UTC

Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19 A Randomized Clinical Trial – JAMA

Commentary: Convalescent plasma futile as treatment for critically ill COVID-19 patients, study finds – University of Pittsburgh

Related:

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

 

New Zealand acknowledges it can no longer completely get rid of the coronavirus.

5 Oct, 2021 | 10:02h | UTC

New Zealand acknowledges it can no longer completely get rid of the coronavirus – NPR

See also:

Navigating from SARS-CoV-2 elimination to endemicity in Australia, Hong Kong, New Zealand, and Singapore – The Lancet

New Zealand admits it can no longer get rid of coronavirus – Associated Press

Battling Delta, New Zealand Abandons Its Zero-Covid Ambitions – The New York Times

 

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

5 Oct, 2021 | 09:57h | UTC

A Pill For COVID? | A Doctor Explains Molnupiravir – ZDoggMD

 

COVID-19 and metabolic disease: mechanisms and clinical management.

5 Oct, 2021 | 10:03h | UTC

COVID-19 and metabolic disease: mechanisms and clinical management – The Lancet Diabetes & Endocrinology

Related: Review | Interplay between endocrinology, metabolism, and COVID-19 infection.

 

Merck’s Covid-19 pill is great news but may not be a game-changer.

5 Oct, 2021 | 09:59h | UTC

Merck’s Covid-19 pill is great news but may not be a game-changer – CNN

 

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

3 Oct, 2021 | 23:02h | UTC

Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study

Commentaries:

Expert reaction to interim analysis of oral antiviral molnupiravir – Science Media Centre

Merck’s antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment – STAT

Covid antiviral pill can halve risk of hospitalization – BBC

Why Merck’s Covid-19 pill molnupiravir could be so important – Vox

‘Unquestionably a game changer!’ Antiviral pill cuts COVID-19 hospitalization risk – Researchers excited about Merck drug, but caution data are preliminary and price is high – Science

 

Commentaries on Twitter

(thread – click for more)

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.